Board Meeting Outcomes
The Board of Directors of Clinitech Laboratory Limited met on November 13, 2026 (12:00 PM to 1:00 PM IST) and:
- Approved the Un-Audited Standalone & Consolidated Financial Results along with Limited Review Report for the half year ended September 30, 2026
- Considered and noted utilization of IPO Proceeds
- Took note of Internal Audit report for the half year ended September 30, 2026
Standalone Financial Performance (H1 FY27)
Income Statement:
- Revenue from operations: ₹947.50 lakh (compared to ₹439.48 lakh in H1 FY26)
- Other income: ₹18.81 lakh (compared to ₹7.81 lakh in H1 FY26)
- Total Income: ₹551.82 lakh (compared to ₹447.29 lakh in H1 FY26)
Expenses:
- Cost of Consumables Used: ₹225.01 lakh
- Laboratory Testing Charges: ₹16.04 lakh
- Employee benefits expense: ₹165.82 lakh
- Finance costs: ₹2.99 lakh
- Depreciation and Amortization Expense: ₹30.07 lakh
- Other Expenses: ₹282.96 lakh
- Total expenses: ₹421.98 lakh
Profitability:
- Profit before tax: ₹34.99 lakh (compared to ₹25.31 lakh in H1 FY26)
- Tax expense: ₹10.53 lakh (Current tax: ₹9.58 lakh, Deferred tax: ₹0.95 lakh)
- Profit After Tax: ₹24.46 lakh (compared to ₹12.23 lakh in H1 FY26)
- Basic EPS: ₹1.07 (compared to ₹0.59 in H1 FY26)
- Diluted EPS: ₹1.07 (compared to ₹0.59 in H1 FY26)
Balance Sheet (Standalone as of September 30, 2026):
- Total Equity and Liabilities: ₹1,193.76 lakh
- Share capital: ₹228.24 lakh (unchanged from March 31, 2026)
- Reserves and Surplus: ₹721.51 lakh (increased from ₹697.04 lakh)
- Long-Term Borrowings: ₹86.44 lakh (increased from ₹35.76 lakh)
- Trade Payables: ₹54.34 lakh (Micro and small enterprises: ₹35.35 lakh, Other creditors: ₹18.99 lakh)
- Total Assets: ₹1,193.76 lakh
- Property, Plant and Equipment: ₹267.62 lakh
- Intangible assets: ₹2.80 lakh
- Intangible Assets under development: ₹99.33 lakh
- Cash and Cash Equivalents: ₹187.20 lakh
- Trade Receivables: ₹225.10 lakh
Cash Flow (Standalone H1 FY27):
- Net Cash from Operating Activities: ₹13.71 lakh
- Net Cash used in Investing Activities: ₹(81.80) lakh
- Net Cash from Financing Activities: ₹48.82 lakh
- Net decrease in Cash and Cash Equivalents: ₹(19.26) lakh
- Cash and Cash Equivalents at End: ₹187.20 lakh
Consolidated Financial Performance (H1 FY27)
Income Statement:
- Revenue from operations: ₹942.41 lakh
- Other income: ₹2.79 lakh
- Total Income: ₹945.20 lakh
Expenses:
- Cost of Consumables Used: ₹406.26 lakh
- Laboratory Testing Charges: ₹16.04 lakh
- Employee benefits expense: ₹192.81 lakh
- Finance costs: ₹12.44 lakh
- Depreciation and Amortization Expense: ₹30.37 lakh
- Other Expenses: ₹225.85 lakh
- Total expenses: ₹883.77 lakh
Profitability:
- Profit before tax: ₹61.43 lakh
- Tax expense: ₹17.19 lakh
- Profit After Tax before Minority Interest: ₹44.24 lakh
- Minority Interest: ₹(7.91) lakh
- Profit attributable to owners: ₹36.33 lakh
- Basic EPS: ₹1.59
- Diluted EPS: ₹1.59
Balance Sheet (Consolidated as of September 30, 2026):
- Total Equity and Liabilities: ₹1,479.64 lakh
- Share capital: ₹228.24 lakh
- Reserves and Surplus: ₹732.93 lakh
- Minority Interest: ₹8.41 lakh
- Long-Term Borrowings: ₹308.20 lakh
- Total Assets: ₹1,479.64 lakh
- Property, Plant and Equipment: ₹359.64 lakh
- Cash and Cash Equivalents: ₹197.45 lakh
- Trade Receivables: ₹354.18 lakh
Cash Flow (Consolidated H1 FY27):
- Net Cash used in Operating Activities: ₹(118.24) lakh
- Net Cash used in Investing Activities: ₹(148.32) lakh
- Net Cash from Financing Activities: ₹252.78 lakh
- Net decrease in Cash and Cash Equivalents: ₹(13.77) lakh
- Cash and Cash Equivalents at End: ₹197.45 lakh
IPO Proceeds Utilization
As of September 30, 2026, the company has fully utilized IPO proceeds of ₹578.30 lakh:
- Expansion of Diagnostic Business: ₹498.67 lakh (100% utilized)
- General Corporate Purposes: ₹41.33 lakh (100% utilized)
- Issue Related Expenses: ₹38.30 lakh (100% utilized)
- Total utilization: ₹578.30 lakh with zero unutilized amount
Additional Information
- The company's registered office: AL 1 545/546, sec 16 Airoli, Opp. Smt. Radhikabai Meghe Vidyalaya, Navi Mumbai - 400 708